home > publications and presentations


Publications

Right Green ArrowARROW publications and presentations - May 2012


Publications from the DART trial are available on the DART website.

1)P Nahirya-Ntege, A Cook, T Vhembo, W Opilo, R Namuddu, R Katuramu, J Tezikyabbiri, B Naidoo-James, D Gibb, on behalf of the ARROW Trial Team. Young HIV-Infected children and their adult caregivers prefer tablets to syrup antiretroviral medications in Africa. PloS ONE 7(5): e36186. doi:10.1371/journal.pone.0036186

2) P Kasirye, L Kendall, KK Adkison, C Tumusiime, M Ssenyonga, S Bakeera-Kitaka, P Nahirya-Ntege, T Mhute, A Kekitiinwa, W Snowden, DM Burger, DM Gibb, AS Walker on behalf of the ARROW trial team. Pharmacokinetics of oral solution versus tablet formulation varies with antiretroviral drug in the target population of HIV-1 infected children. Clinical Pharmacology and Therapeutics 2011 Dec 21;10.1038/clpt.2011.225

3) Q Fillekes, E Natukunda, J Balungi, L Kendall, M Bwakura-Dangarembizi, R Keishanyu, A Ferrier, J Lutakome, DM Gibb, DM Burger, AS Walker on behalf of the ARROW trial team. Paediatric under-dosing of Efavirenz: a pharmacokinetic study in Uganda. Journal of Acquired Immune Deficiency Syndromes 2011 Dec 1;58(4):392-8.

4) A Prendergast, M Bwakura-Dangarembizi, A Cook, S Bakeera-Kitaka, E Natukunda, P Nahirya, K Nathoo, C Karungi, J Lutaakome, A Kekitiinwa, D M Gibb. Acute kwashiorkor in HIV-infected African children starting antiretroviral therapy in the ARROW trial. AIDS 2011 Apr 24;25(7):951-6

5) P Nahirya-Ntege, V Musiime, B Naidoo, S Bakeera-Kitaka, K Nathoo, P Munderi, P Mugyenyi, A Kekitiinwa, MF Bwakura-Dangarembizi, J Crawley on behalf of the ARROW trial team. Low incidence of abacavir hypersensitivity reaction among African children initiating antiretroviral therapy. Paediatric Infectious Disease Journal
10.1097/INF.0b013e3182076864


6) V Musiime, L Kendall, S Bakeera-Kitaka, W Snowden, F Odongo, M Thomason, P Musoke, K Addison, David Burger, P Mugyenyi, A Kekitiinwa, DM Gibb, AS Walker on behalf of the ARROW trial team. Pharmacokinetics and acceptability of once versus twice daily lamivudine and abacavir in HIV-1 infected Ugandan children in the ARROW trial. Antiviral Therapy 10.3851/IMP1695.

Posters

Right Green Arrow1. Weight gain in children initiating ART is not increased by nutritional supplements.

19th Conference on retroviruses and opportunistic infections, 5-8 March 2012, Seattle, Washington

Right Green Arrow2. Long term profiles of CD4 reconstitution in HIV-infected Children initiating Antiretroviral Therapy in Uganda and Zimbabwe.

19th Conference on retroviruses and opportunistic infections, 5-8 March 2012, Seattle, Washington.

Right Green Arrow3. Bacteriology of ear discharge in HIV-infected children on ART in the ARROW trial in Uganda and Zimbabwe.

3rd International Workshop on HIV Paediatrics, 15 – 16 July 2011 / 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 17 – 20 July 2011, Rome, Italy

Right Green Arrow4. Bacteraemia in HIV-1 infected children on antiretroviral therapy in Uganda and Zimbabwe in the ARROW clinical trial.

6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 17 – 20 July 2011, Rome, Italy

Right Green Arrow5. PK of ZDV dosed twice-daily according to who weight-bands in African hiv-1-infected children.

18th Conference on retroviruses and opportunistic infections, 27 February – 2 March 2011, Boston, Massachusetts

Right Green Arrow6. CD4 T cell depletion, and not age, drives reconstitution within CD4 cell compartments in HIV-infected children initiating ART in Uganda.

18th Conference on retroviruses and opportunistic infections, 27 February – 2 March 2011, Boston, Massachusetts

Right Green Arrow7. Pharmacokinetics of lamivudine, abacavir and Zidovudine administered twice-daily as syrups versus Scored tablets in HIV-1 infected Ugandan children.

Tenth International Congress on Drug Therapy in HIV Infection, 7 - 11 November 2010, Glasgow, United Kingdom

Right Green Arrow8. Tablets are more acceptable and give fewer problems than syrups among young HIV-infected children in resource limited settings in the ARROW trial.

2nd International Workshop on HIV Paediatrics, 16 – 17 July 2010 and XVIII International AIDS Conference, 18 – 23 July 2010, Vienna, Austria

Right Green Arrow9. Disclosure of their HIV status to HIV-infected children participating in the ARROW trial in Entebbe, Uganda.

2nd International Workshop on HIV Paediatrics, 16 – 17 July 2010 and XVIII International AIDS Conference, 18 – 23 July 2010, Vienna, Austria

Right Green Arrow10. CD4 depletion, and not age, may be a driver of abnormal CD4 cell compartments in HIV-infected children initiating ART in Uganda.

17th Conference on retroviruses and opportunistic infections, 16 – 19 February 2010, San Francisco, California

Right Green Arrow11. Pharmacokinetics of Efavrinez dosed according to the WHO weight-bands in children in Uganda.

17th Conference on retroviruses and opportunistic infections, 16 – 19 February 2010, San Francisco, California

Right Green Arrow12. Successful management of suspected Abacavir HSRs in African children

5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 19-22 July 2009, Cape Town, South Africa / 1st International Workshop on HIV Pediatrics, 17-18 July 2009, Cape Town, South Africa

Right Green Arrow13. HIV-status and healthcare needs of primary caregivers of HIV-infected children in Zimbabwe

5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 19-22 July 2009, Cape Town, South Africa

Right Green Arrow14. Acute kwashiorkor soon after initiating ART among HIV infected children

5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 19-22 July 2009, Cape Town, South Africa / 1st International Workshop on HIV Pediatrics, 17-18 July 2009, Cape Town, South Africa

Right Green Arrow15. PK of Once versus Twice Daily Lamivudine and Abacavir in HIV-1 Infected Ugandan Children

5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 19-22 July 2009, Cape Town, South Africa / 1st International Workshop on HIV Pediatrics, 17-18 July 2009, Cape Town, South Africa

Right Green Arrow16. Confidentiality and non-disclosure can affect enrolment, follow-up and adherence to ART

XVII International AIDS Conference, 3-8 August 2008, Mexico City

Right Green Arrow17. ARROW study design and baseline characteristics

XVII International AIDS Conference, 3-8 August 2008, Mexico City

Right Green Arrow18. Ethical and practical constraints to the participation of HIV-infected orphaned children in a clinical trial in Zimbabwe

XVII International AIDS Conference, 3-8 August 2008, Mexico City


Oral

Right Green Arrow1. Bacteriology of ear discharge in HIV-infected children on ART in the ARROW trial in Uganda and Zimbabwe.

5th National Paediatric HIV and AIDS Conference, 29 September 2011, Kampala Uganda

Right Green Arrow2. Bacteraemia in HIV-1 infected children on antiretroviral therapy in Uganda and Zimbabwe in the ARROW clinical trial.

3rd International Workshop on HIV Paediatrics, 15 – 16 July 2011, Rome, Italy

Right Green Arrow3. Early mortality following ART initiation in HIV-infected adults and children in Uganda and Zimbabwe.

Tenth International Congress on Drug Therapy in HIV Infection, 7 - 11 November 2010, Glasgow, United Kingdom

Right Green Arrow4. CD4 depletion, and not age, may be a driver of abnormal CD4 cell compartments in HIV-infected children initiating ART in Uganda.

4th National Paediatric HIV/AIDS conference, 28 – 30 September 2010, Kampala, Uganda

Right Green Arrow5. Tablets are more acceptable and give fewer problems than syrups among young HIV-infected children in resource limited settings in the ARROW trial.

4th National Paediatric HIV/AIDS conference, 28 – 30 September 2010, Kampala, Uganda

Right Green Arrow6. Comparison between calculated and direct measurements of CD4 percentage for immunological monitoring of antiretroviral therapy in children.

4th National Paediatric HIV/AIDS conference, 28 – 30 September 2010, Kampala, Uganda

Right Green Arrow7. Disclosure of their HIV status to HIV-infected children participating in the ARROW trial in Entebbe, Uganda.

4th National Paediatric HIV/AIDS conference, 28 – 30 September 2010, Kampala, Uganda

Right Green Arrow8. Pharmacokinetics of Efavrinez dosed according to the WHO weight-bands in children in Uganda.

4th National Paediatric HIV/AIDS conference, 28 – 30 September 2010, Kampala, Uganda